



# COVID-19 Research and Innovation

**Powering the world's pandemic response – now and in the future**

**Global research and Innovation Forum**  
24<sup>th</sup>-25<sup>th</sup> February 2022



**World Health  
Organization**



**R&D Blueprint**  
Powering research  
to prevent epidemics



# WHO R&D Blueprint for epidemics



At the request of its 194 Member States in May 2015, the World Health Organization convened a broad network of experts to develop an [R&D Blueprint for Epidemics](#).

A global strategy and preparedness plan was developed to allow for the rapid activation of research before and during epidemics.

...By embedding research at the heart of the pandemic response, we can achieve two goals: to help us end the acute phase of the current pandemic, and to protect us from the epidemics and pandemics of the future....

# Governments and international community needs to work together to be better prepared

The World Health Assembly agreed on December 2021 to launch negotiations for an agreement to fight pandemics.

The 194 Member States of the World Health Organization reached a consensus to **kickstart the process to draft and negotiate a convention, agreement or other international instrument under the Constitution of the World Health Organization to strengthen pandemic prevention, preparedness and response.**

# Governments and international community needs to work together to be better prepared

**WHO** has defined as a priority to harness the power of science, research innovation, data and digital **technologies** as critical enablers of the other priorities – for health promotion and disease prevention, for early diagnosis and case management, and for the prevention, early detection, and rapid response to epidemics and pandemics.

# Some of the next priorities ...

It is crucial to attend to and protect the most at-risk populations, and to be aware that the short- and medium-term impact of the pandemic have been particularly severe for the most disadvantaged and have worsened existing socio-economic divides


## Democratize research




# Inclusive global platforms to facilitate research

## Registered researchers across the globe working to combat COVID-19

Over 5,000 researchers from 171 countries are now registered / collaborating to implement COVID-19 R&D.



A flexible, yet comprehensive architecture to address research... from A to Z





# Some of next priorities ...


**Pragmatic adaptive trial designs should be prioritized and smaller, underpowered clinical discouraged.**

**Also, in a global trial, with different geographical needs, it should be possible to report different outcomes for different regions of the world.** A composite endpoint that allows study participants to be graded along the full spectrum of possible outcomes could be ideal for this scenario.

# Global platform **SOLIDARITY** studies and trials with the national researchers and governments at the heart of it...

## 1. Therapeutics

### COVID-19 Solidarity PLUS Therapeutics Trial



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: WHO  
Map Production: WHO GIS Centre for Health, DfA/DDI  
Map Creation Date: 20 January 2022



## 2. Serosurveys

### Solidarity II - a global serologic study for COVID-19

442 research representatives from 65 countries are co-ordinating globally to better understand how the virus affects different populations across the world



Solidarity II is a global collaboration led by the World Health Organization that promotes the implementation of serological surveys of SARS-CoV-2.

The collaboration will provide key data to help the world understand many key issues:

- how frequently SARS-CoV-2 infection occurs among different populations
- how many people have had mild or asymptomatic infection

- how many people have been infected but may not have been identified
- what proportion of the population may be immune to infection by SARS-CoV-2

This map shows there are over 442 research representatives from 65 countries taking part in this global data effort to better understand how the virus is affecting different populations across the world

## 3. Vaccines

### Solidarity Trial Vaccines




# Global studies with the national researchers and governments at the heart of it...



Figure 1: the WHO IPC Teams coordinated 45 research projects, which included 27 multicentre studies in 45 different states in order to generate evidence on the research priorities identified in February 2020

Countries with at least one seroprevalence study aligning with **WHO UNITY protocol**, 1 January 2020– 31 Dec 2021



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization  
Map Production: WHO Health Emergencies Programme  
Request ID: COVID19\_46



© WHO 2022. All rights reserved.



# trust

/trəst/

***noun*** firm belief in the reliability, truth, ability, or strength of someone or something.

"relationships have to be built on trust"

*synonyms:* confidence, belief, faith, certainty, assurance, conviction, credence

**To make progress on research, the scientific community relies on information sharing, reagent sharing, and resources (human and financial).**

As we address the current pandemic, we also need to prepare for the future taking in consideration the importance of preparation, of achieving both speed and rigor, the importance of collaboration, the importance of global equity and the importance of sustained efforts.

**Existing processes and platforms will be the foundation for the research response for future epidemics, pandemics and other global health emergencies.**



**The global coordination and support of the world's leading scientists and experts does not always grab the media headlines**

**But it has been key in underpinning the important initiatives and breakthroughs achieved in research and innovation**

**Thank you !**

# Thank you

**Above all thanks to thousands of the volunteers across the world the made the trials and studies possible!**

**Over 5000** scientists contributing to deliberations, sharing results results, supporting and conducting critical research from almost every one of the 194 member states of WHO.

**Numerous funders supporting critical research**

**Nearly 40** colleagues across WHO contributing to the R&D Blueprint objectives



World Health Organization

Health Topics ▾

Countries ▾

Newsroom ▾

Emergencies ▾

Data ▾

World Health Organization



**Download** the Achievement Report: COVID-19 Research and Innovation Powering the world's pandemic response – now and in the future

